Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, provided Q2 2025 updates on its clinical progress and financial results. The company's pivotal Phase 3 trial for early Alzheimer's disease has secured 76 U.S. clinical sites, with 38 patients already receiving treatment and approximately 200 more in screening.
Key operational highlights include the appointment of Hui Liu as Director of Biostatistics, successful presentations at AAIC 2025, and the completion of patent family transfers to crystal buntanetap. Financially, Annovis reported cash and equivalents of $17.1 million as of June 30, 2025, with reduced R&D expenses of $5.2 million and G&A expenses of $1.1 million for Q2 2025. The company's net loss per share improved to $0.32 compared to $0.44 in the same quarter last year.
Annovis Bio (NYSE: ANVS), azienda farmaceutica in fase clinica avanzata specializzata nelle malattie neurodegenerative, ha fornito aggiornamenti del secondo trimestre 2025 sul progresso clinico e sui risultati finanziari. Il trial di Fase 3 cruciale per l'Alzheimer in fase iniziale ha coinvolto 76 siti clinici negli Stati Uniti, con 38 pazienti gi脿 in trattamento e circa 200 ulteriori in fase di screening.
I principali elementi operativi includono la nomina di Hui Liu a Direttore della Biostatistica, presentazioni di successo all'AAIC 2025 e il completamento del trasferimento delle famiglie di brevetti a crystal buntanetap. Sul piano finanziario, Annovis ha dichiarato liquidit脿 e mezzi equivalenti di $17.1 million al 30 giugno 2025, con costi di R&S ridotti a $5.2 million e spese G&A pari a $1.1 million per il secondo trimestre 2025. Il risultato netto per azione 猫 migliorato a $0.32 rispetto a $0.44 nello stesso periodo dell'anno precedente.
Annovis Bio (NYSE: ANVS), una compa帽铆a farmac茅utica en fase cl铆nica avanzada centrada en enfermedades neurodegenerativas, present贸 actualizaciones del segundo trimestre de 2025 sobre su avance cl铆nico y sus resultados financieros. El ensayo pivotal de Fase 3 para la enfermedad de Alzheimer en etapa temprana cuenta con 76 sitios cl铆nicos en EE. UU., con 38 pacientes ya recibiendo tratamiento y aproximadamente 200 m谩s en cribado.
Los aspectos operativos clave incluyen el nombramiento de Hui Liu como Directora de Bioestad铆stica, presentaciones exitosas en AAIC 2025 y la finalizaci贸n de las transferencias de familias de patentes a crystal buntanetap. En lo financiero, Annovis inform贸 de efectivo y equivalentes por $17.1 million al 30 de junio de 2025, con gastos de I+D reducidos a $5.2 million y gastos G&A de $1.1 million en el segundo trimestre de 2025. La p茅rdida neta por acci贸n mejor贸 a $0.32 frente a $0.44 en el mismo trimestre del a帽o anterior.
Annovis Bio (NYSE: ANVS)電� 鞁犼步韲错枆靹� 歆堩櫂鞐� 欤茧牓頃橂姅 頉勱赴 鞛勳儊 雼硠鞚� 鞁犾暯 頂岆灚韽� 旮办梾鞙茧靹� 2025雲� 2攵勱赴 鞛勳儊 歆勴枆 靸來櫓 氚� 鞛 瓴瓣臣毳� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 須岇偓鞚� 齑堦赴 鞎岇笭頃橃澊毹鸽硲鞚� 雽�靸侅溂搿� 頃� 頃奠嫭 3靸� 鞁滍棙鞚� 氙戈淡 雮� 76臧� 鞛勳儊 靷澊韸鸽ゼ 頇曤炒頄堨溂氅�, 鞚措 38氇呾澊 旃橂毳� 氚涥碃 鞛堦碃 鞎� 200氇呹皜霟夓澊 鞀ろ伂毽嫕 欷戩瀰雼堧嫟.
欤检殧 鞖挫榿 頃橃澊霛检澊韸鸽電� Hui Liu鞚� 靸濍韱店硠頃� 鞚挫偓 靹犾瀯, AAIC 2025鞐愳劀鞚� 靹标车鞝� 氚滍憸, 攴鸽Μ瓿� 韸鬼棃 甑办潣 crystal buntanetap搿滌潣 鞚挫爠 鞕勲臧� 韽暔霅╇媹雼�. 鞛鞝侅溂搿� Annovis電� 2025雲� 6鞗� 30鞚� 旮办 順勱笀 氚� 順勱笀靹� 鞛愳偘 $17.1 million鞚� 氤搓碃頄堨溂氅�, 2025雲� 2攵勱赴 鞐瓣惮臧滊皽牍勲姅 $5.2 million, 鞚茧皹甏�毽箘電� $1.1 million搿� 臧愳唽頄堨姷雼堧嫟. 欤茧嫻 靾滌啇鞁れ潃 鞝勲厔 霃欔赴 $0.44鞐愳劀 臧滌劆霅� $0.32毳� 旮半頄堨姷雼堧嫟.
Annovis Bio (NYSE: ANVS), soci茅t茅 de biotechnologie en phase clinique avanc茅e sp茅cialis茅e dans les maladies neurod茅g茅n茅ratives, a publi茅 des mises 脿 jour du deuxi猫me trimestre 2025 sur ses progr猫s cliniques et ses r茅sultats financiers. L'essai pivot de Phase 3 pour la maladie d'Alzheimer pr茅coce a mobilis茅 76 sites cliniques aux 脡tats-Unis, avec 38 patients d茅j脿 trait茅s et environ 200 autres en phase de s茅lection.
Les faits marquants op茅rationnels incluent la nomination de Hui Liu au poste de directrice de la biostatistique, des pr茅sentations r茅ussies 脿 l'AAIC 2025 et l'ach猫vement des transferts de familles de brevets vers crystal buntanetap. Sur le plan financier, Annovis a d茅clar茅 des liquidit茅s et 茅quivalents de $17.1 million au 30 juin 2025, avec des d茅penses R&D r茅duites 脿 $5.2 million et des frais G&A de $1.1 million pour le deuxi猫me trimestre 2025. La perte nette par action s'est am茅lior茅e 脿 $0.32 contre $0.44 au m锚me trimestre de l'ann茅e pr茅c茅dente.
Annovis Bio (NYSE: ANVS), ein sp盲tphasiges klinisches Pharmaunternehmen mit Fokus auf neurodegenerative Erkrankungen, gab Updates zum zweiten Quartal 2025 zu seinem klinischen Fortschritt und den Finanzergebnissen bekannt. Die entscheidende Phase-3-Studie f眉r fr眉he Alzheimer-Erkrankung umfasst 76 klinische Standorte in den USA; 38 Patienten erhalten bereits die Behandlung und etwa 200 weitere befinden sich im Screening.
Zu den wichtigen operativen Punkten z盲hlen die Ernennung von Hui Liu zur Direktorin der Biostatistik, erfolgreiche Pr盲sentationen auf der AAIC 2025 und der Abschluss der 脺bertragung von Patentfamilien an crystal buntanetap. Finanzseitig meldete Annovis Barmittel und Zahlungsmittel盲quivalente in H枚he von $17.1 million zum 30. Juni 2025, mit reduzierten F&E-Aufwendungen von $5.2 million und G&A-Aufwendungen von $1.1 million im zweiten Quartal 2025. Der Verlust je Aktie verbesserte sich auf $0.32 gegen眉ber $0.44 im gleichen Quartal des Vorjahres.
- Clinical trial progress with 76 secured sites and 38 patients already receiving treatment
- Cash position improved to $17.1 million from $10.6 million in December 2024
- Reduced net loss per share to $0.32 from $0.44 year-over-year
- Decreased operating expenses with R&D at $5.2M (vs $5.8M) and G&A at $1.1M (vs $2.0M)
- 50% screen failure rate in clinical trials
- Continued net losses indicate ongoing cash burn
Insights
Annovis shows progress in Phase 3 Alzheimer's trial with 76 sites secured, reduced expenses, and improved cash position despite ongoing R&D investments.
Annovis Bio's Q2 2025 update demonstrates meaningful progress in its Phase 3 Alzheimer's disease program, with 76 clinical sites secured and 46 actively enrolling patients. The company has already dosed 38 subjects with either buntanetap or placebo, while nearly 200 more participants are in the screening pipeline. The 50% screen failure rate aligns with expectations for neurodegenerative disease trials, suggesting appropriate patient selection protocols.
On the financial front, Annovis has strengthened its position with
The successful transfer of all patent families to crystal buntanetap represents a critical intellectual property milestone, potentially extending exclusivity protection and enhancing the commercial value proposition. This strategic move, combined with the company's expanding clinical footprint and robust scientific presence at AAIC 2025, demonstrates management's focus on building long-term value while executing on near-term clinical goals for their neurodegenerative disease platform.
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the 鈥淐ompany鈥�), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results.
鈥淚n the past quarter, our efforts were centered on driving enrollment for the pivotal Phase 3 trial in early AD, which now includes 76 secured clinical sites across the U.S. and over 400 patients screened to date,鈥� said Maria Maccecchini, Ph.D., President and CEO of Annovis. 鈥淎t the same time, we reached other notable milestones, including presenting our latest scientific findings at AAIC 2025 with the largest attendance ever from Annovis team and strengthening our global intellectual property protection by completing the transfer of all patent families to crystal buntanetap. As we move forward, our focus stays firmly on completing enrollment as planned to produce strong and trustworthy results, while also advancing our Parkinson鈥檚 program, with more updates coming as we progress.鈥�
Clinical highlights
- Annovis鈥� pivotal Phase 3 study in early AD () is advancing rapidly, with 76 U.S. sites secured and 46 currently enrolling patients. The remaining sites are expected to begin enrollment shortly.
- The pivotal Phase 3 trial has attracted strong participation, with 38 patients already receiving buntanetap or placebo and nearly 200 more in screening 鈥� a number that continues to grow each day 鈥� with screen failure rate being as expected at
50% .
Business highlights
- In April, Annovis welcomed Hui Liu as Director of Biostatistics, who is responsible for maintaining statistical integrity of the data generated by the Company鈥檚 clinical trials.
- In June, Annovis hosted a webcast to provide updates on its Phase 3 trial, engaging directly with the audience through a live Q&A session. The recording is available in the on the Company鈥檚 website.
- In July, senior members of Annovis attended AAIC 2025 in Toronto, presenting four scientific posters highlighting advancements in the Alzheimer鈥檚 Phase 3 study and the pharmacokinetic profile of its lead drug candidate, buntanetap. All posters are available in the on the Company鈥檚 website.
- In August, Annovis announced the successful transfer of all patent families to crystal buntanetap, achieving comprehensive global IP coverage for both the original and new forms of the Company鈥檚 drug candidate.
Financial results
- Annovis鈥� cash and cash equivalents totaled
$17.1 million as of June 30, 2025, compared to$10.6 million as of December 31, 2024. The Company had 19.5 million shares of common stock outstanding as of June 30, 2025. - Research and development expenses for the three months ending June 30, 2025, were
$5.2 million compared to$5.8 million for the three months ending June 30, 2024. - General and administrative expenses for the three months ending June 30, 2025, were
$1.1 million compared to$2.0 million for the three months ending June 30, 2024. - Annovis reported a
$0.32 b asic and diluted net loss per common share for the three months ending June 30, 2025, compared to a$0.44 b asic and diluted net loss per common share for the three months ending June 30, 2024.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on , , and .
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at .
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company鈥檚 SEC filings under 鈥淩isk Factors鈥� in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
(Tables to follow)
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| ANNOVIS BIO, INC. | |||||||
| Balance Sheets | |||||||
| (Unaudited) | |||||||
| 听 | 听 | 听 | 听 | ||||
| 听 | June 30, | 听 | December听31, | ||||
| 听 | 2025 | 听 | 2024 | ||||
| Assets | 听 | 听 | 听 | 听 | 听 | ||
| Current assets: | 听 | 听 | 听 | 听 | 听 | ||
| Cash and cash equivalents | $ | 17,130,286 | 听 | 听 | $ | 10,551,916 | 听 |
| Prepaid expenses and other current assets | 听 | 4,324,285 | 听 | 听 | 听 | 3,373,717 | 听 |
| Total assets | $ | 21,454,571 | 听 | 听 | $ | 13,925,633 | 听 |
| Liabilities and stockholders鈥� equity | 听 | 听 | 听 | 听 | 听 | ||
| Current liabilities: | 听 | 听 | 听 | 听 | 听 | ||
| Accounts payable | $ | 974,311 | 听 | 听 | $ | 2,305,974 | 听 |
| Accrued expenses | 听 | 1,830,813 | 听 | 听 | 听 | 1,575,013 | 听 |
| Total current liabilities | 听 | 2,805,124 | 听 | 听 | 听 | 3,880,987 | 听 |
| Non-current liabilities: | 听 | 听 | 听 | 听 | 听 | ||
| Warrant liability | 听 | 319,000 | 听 | 听 | 听 | 737,000 | 听 |
| Total liabilities | 听 | 3,124,124 | 听 | 听 | 听 | 4,617,987 | 听 |
| Commitments and contingencies | 听 | 听 | 听 | 听 | 听 | ||
| Stockholders鈥� equity: | 听 | 听 | 听 | 听 | 听 | ||
| Preferred stock - | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Common stock - | 听 | 1,948 | 听 | 听 | 听 | 1,414 | 听 |
| Additional paid-in capital | 听 | 164,935,088 | 听 | 听 | 听 | 144,155,694 | 听 |
| Accumulated deficit | 听 | (146,606,589 | ) | 听 | 听 | (134,849,462 | ) |
| Total stockholders鈥� equity | 听 | 18,330,447 | 听 | 听 | 听 | 9,307,646 | 听 |
| Total liabilities and stockholders鈥� equity | $ | 21,454,571 | 听 | 听 | $ | 13,925,633 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| ANNOVIS BIO, INC. | |||||||||||||||
| Statements of Operations | |||||||||||||||
| (Unaudited) | |||||||||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| 听 | Three Months Ended | 听 | Six Months Ended | ||||||||||||
| 听 | June 30, | 听 | June听30, | ||||||||||||
| 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 2024 | ||||||||
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Research and development | $ | 5,161,921 | 听 | 听 | $ | 5,785,217 | 听 | 听 | $ | 10,173,438 | 听 | 听 | $ | 12,307,308 | 听 |
| General and administrative | 听 | 1,109,532 | 听 | 听 | 听 | 1,977,421 | 听 | 听 | 听 | 2,380,696 | 听 | 听 | 听 | 3,265,137 | 听 |
| Total operating expenses | 听 | 6,271,453 | 听 | 听 | 听 | 7,762,638 | 听 | 听 | 听 | 12,554,134 | 听 | 听 | 听 | 15,572,445 | 听 |
| Operating loss | 听 | (6,271,453 | ) | 听 | 听 | (7,762,638 | ) | 听 | 听 | (12,554,134 | ) | 听 | 听 | (15,572,445 | ) |
| Other income (expense): | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Interest income | 听 | 191,395 | 听 | 听 | 听 | 25,978 | 听 | 听 | 听 | 379,007 | 听 | 听 | 听 | 70,146 | 听 |
| Other financing costs | 听 | 鈥� | 听 | 听 | 听 | (1,346,060 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (1,346,060 | ) |
| Change in fair value of warrants | 听 | (140,000 | ) | 听 | 听 | 4,062,308 | 听 | 听 | 听 | 418,000 | 听 | 听 | 听 | 10,761,000 | 听 |
| Total other income, net | 听 | 51,395 | 听 | 听 | 听 | 2,742,226 | 听 | 听 | 听 | 797,007 | 听 | 听 | 听 | 9,485,086 | 听 |
| Net loss | $ | (6,220,058 | ) | 听 | $ | (5,020,412 | ) | 听 | $ | (11,757,127 | ) | 听 | $ | (6,087,359 | ) |
| Net loss per share | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Basic | $ | (0.32 | ) | 听 | $ | (0.44 | ) | 听 | $ | (0.64 | ) | 听 | $ | (0.56 | ) |
| Diluted | $ | (0.32 | ) | 听 | $ | (0.44 | ) | 听 | $ | (0.64 | ) | 听 | $ | (1.52 | ) |
| Weighted-average number of common shares used in computing net loss per share | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Basic | 听 | 19,486,231 | 听 | 听 | 听 | 11,307,759 | 听 | 听 | 听 | 18,464,877 | 听 | 听 | 听 | 10,966,412 | 听 |
| Diluted | 听 | 19,486,231 | 听 | 听 | 听 | 11,307,759 | 听 | 听 | 听 | 18,464,877 | 听 | 听 | 听 | 11,066,265 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
FAQ
What is the status of Annovis Bio's (ANVS) Phase 3 Alzheimer's trial in Q2 2025?
How much cash does Annovis Bio (ANVS) have as of Q2 2025?
What were Annovis Bio's (ANVS) Q2 2025 financial results?
What major business developments did Annovis Bio (ANVS) announce in Q2 2025?
How many patients are currently enrolled in Annovis Bio's (ANVS) Alzheimer's trial?
